Low omentin-1, high chemerin levels linked to Type 2 diabetes
MedWire News: Serum levels of omentin-1 are significantly lower and chemerin significantly higher in patients with Type 2 diabetes than in nondiabetics, report researchers.
The team found that presence of ischemic heart disease (IHD) in addition to Type 2 diabetes did not appear to affect levels of these biomarkers, and say that further research is needed to assess their role in cardiovascular disease.
Omentin-1 and chemerin are thought to be linked to obesity-induced insulin resistance and glucose regulation. Nadia Hamdy (Ain Shams University, Cairo, Egypt) and colleagues therefore assessed whether levels of these adipokines differed between middle-aged (50-60 years) patients with Type 2 diabetes (n=75) and nondiabetic controls of a similar age (n=15). Twenty-two of the patients with Type 2 diabetes also had IHD.
The researchers found that serum levels of omentin-1 were significantly lower in patients with diabetes, both without and with IHD, compared with controls, at 19.7 and 18.5 ng/ml, respectively, versus 27.4 ng/ml.
Conversely, patients with Type 2 diabetes had significantly higher levels of chemerin than nondiabetics, at 347 and 341 ng/ml in diabetics without and with IHD, respectively, versus 281 ng/ml in nondiabetics.
The team notes that there was a significant negative correlation between the two biomarkers.
In addition, there were positive correlations between chemerin and levels of the inflammatory factor interleukin 6, body mass index (BMI), low-density lipoprotein and total cholesterol, glycated hemoglobin, blood glucose, and insulin and negative correlations between omentin-1 and each of these factors, all of which were significant.
The findings regarding omentin-1 support others reported previously by MedWire News.
"Decreased serum omentin-1 levels observed in Type 2 diabetes may cause a reduction of insulin-stimulated glucose uptake in visceral and subcutaneous adipocytes or other insulin-sensitive tissues. This may contribute to the state of insulin resistance observed in Type 2 diabetes," suggest Hamdy and co-authors in the journal Diabetic Medicine.
"With regard to chemerin… experimental evidence supports its role in various aspects of human physiology/pathophysiology, including obesity, insulin resistance and inflammation," write the authors.
"However, the precise role of chemerin in these disorders remains unclear and several key research questions merit further investigation," they conclude.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011
By Helen Albert